
**[0016]** The current therapies are not satisfactory and therefore there remains a need to identify further compounds that may be of use in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, *e.g.* osteoarthritis, and rheumatoid arthritis , in particular rheumatoid arthritis. The present invention therefore provides a compound, methods for its manufacture and pharmaceutical compositions comprising the compound of the invention together with a suitable pharmaceutical carrier. The present invention also provides for the use of the compound of the invention in the preparation of a medicament for the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, *e.g.* osteoarthritis, and rheumatoid arthritis , in particular rheumatoid arthritis.

## SUMMARY OF THE INVENTION

**[0017]** The present ~~invention~~disclosure is based on the discovery that the compound of the ~~invention~~ disclosure is able to act as inhibitor of JAK and that it is useful for the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. ~~In a specific aspect the compound of the invention~~Also disclosed is an inhibitor of JAK1 and/or JAK2. The present ~~invention~~ disclosure also provides methods for the production of this compound, pharmaceutical compositions comprising this compound and methods for treating inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, by administering the compound of the ~~invention~~disclosure.

**[0018]** Accordingly, in a first aspect of the invention, the compound of the invention provided is according to Formula (I):



I

or a pharmaceutically acceptable salt, or a solvate, or a solvate of the pharmaceutically acceptable salt.

**[0019]** In a particular ~~embodiment~~ example the compound of the invention is an inhibitor of JAK1 and/or JAK2.

**[0020]** In a further aspect, the present invention provides pharmaceutical compositions comprising the compound of the invention, and a pharmaceutical carrier, excipient or diluent. Moreover, the compound of the ~~invention~~disclosure, useful in the pharmaceutical compositions and treatment methods disclosed herein, is pharmaceutically acceptable as prepared and used. In this aspect of the invention, the pharmaceutical composition may additionally comprise further active ingredients suitable for use in combination with the compound of the invention.

**[0021]** ~~In a further aspect of the invention~~Also disclosed is, ~~this invention provides~~ a method of treatment or prophylaxis of a mammal susceptible to or afflicted with a condition from among those listed herein, and particularly, inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and diseases associated with hypersecretion of IL6 or interferons, which method comprises administering an effective amount of the pharmaceutical composition or compound of the ~~invention~~ disclosure as described herein. In a particular ~~embodiment~~ example the condition is associated with aberrant JAK activity, and more particularly JAK1 and/or JAK2 activity.

**[0022]** In a further aspect, the invention provides the compound of the invention for use in medicine. Also disclosed is the compound of the ~~invention~~ disclosure or a pharmaceutical composition comprising the compound of the ~~invention~~ disclosure for use as a medicament. In a specific ~~embodiment~~example, said pharmaceutical composition additionally comprises a further active ingredient.

**[0023]** In another aspect, the present invention provides the use of the compound of the invention in the manufacture of a medicament.

**[0024]** ~~[0023]~~ In a further aspect, the present invention provides the compound of the invention for use in the treatment or ~~prophyaxis~~ prophylaxis of a condition selected from those listed herein, particularly inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

**[0024a]** In yet another aspect, the present invention provides the use of the compound of the invention in the manufacture of a medicament for the treatment or prophylaxis of a condition selected from those listed herein, particularly inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons

**[0025]** ~~[0024] In yet another method of treatment aspect~~Also disclosed is a method of treatment or prophylaxis of a mammal susceptible to or afflicted with a condition selected from those listed herein, particularly inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, and comprises administering an effective amount of the pharmaceutical composition or the compound of the ~~invention~~ disclosure described herein for the treatment or prophylaxis of said condition. In a specific ~~aspect~~ example the condition is causally related to abnormal JAK activity and more particularly JAK1 and/or JAK2 activity.

~~[0025] In a further aspect, the present invention provides the compound of the invention for use in the treatment or prophylaxis of a condition selected from those listed herein, particularlyinflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.~~

**[0026]** ~~In additional aspects, this invention provides~~Also disclosed are methods for synthesizing the compound of the ~~invention~~disclosure, with representative synthetic protocols and pathways disclosed later on herein.

**[0027]** Accordingly, it is a principal object of this ~~invention~~ disclosure to provide a novel compound, which can modify the activity of JAK and thus prevent or treat any conditions that may be causally related thereto. In ~~a specific~~one ~~aspect~~ example the compound of the ~~invention~~ disclosure modulate the activity of JAK1 and/or JAK2.

**[0028]** It is further an object of this ~~invention~~ disclosure to provide a compound that can treat or alleviate conditions or symptoms of same, such as inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons,.

**[0029]** A still further object of this ~~invention~~ disclosure is to provide a pharmaceutical composition that may be used in the treatment or prophylaxis of a variety of disease states, such as inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In a specific ~~embodiment~~ example the disease is associated with JAK1 and/or JAK2 activity, in particular inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

**[0030]** Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing detailed description.

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions

**[0031]** The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention.

**[0032]** When describing the invention, which may include compounds, pharmaceutical compositions containing such compounds and methods of using such compounds and compositions, the following terms, if present, have the following meanings unless otherwise indicated. It should also be understood that when described herein any of the moieties defined forth below may be substituted with a variety of substituents, and that the respective definitions are intended to include such substituted moieties within their scope as set out below. Unless otherwise stated, the term "substituted" is to be defined as set out below. It should be further understood that the terms "groups" and "radicals" can be considered interchangeable when used herein.

**[0033]** The articles "a" and "an" may be used herein to refer to one or to more than one (*i.e.* at least one) of the grammatical objects of the article. By way of example "an analogue" means one analogue or more than one analogue.

**[0034]** As used herein the term 'JAK' relates to the family of Janus kinases (JAKs) which are cytoplasmic tyrosine kinases that transduce cytokine signaling from membrane receptors to STAT transcription factors. Four JAK family members are described, JAK1, JAK2, JAK3 and TYK2 and the